SyndicateRoom

Access EIS portfolio company Concr today announced that the first patients have been recruited to its observational study aimed at transforming the treatment of early triple-negative breast cancer (TNBC). Wishing the team and the patients the very best of luck. Concr is a value-driven techbio company, applying statistical learning and advanced modelling adopted from astrophysics to aid in precision treatment of cancer patients Find out more about Concr here https://concr.co/, or read on for the full release:

Huge congratulations to Access EIS portfolio company MOTH Drinks - B Corp™ on winning "Drinks Brand of the Year" at the Grocer Gold awards! Find out more about Moth - which is now sold every ten seconds in supermarkets - here: https://mothdrinks.com/

Huge congratulations to Access EIS portfolio company Heatio and team for the finalisation of their latest funding round! Read on to find out more about how Heatio is revolutionising home energy management. Simon Roberts Thomas Farquhar

Access EIS portfolio company Invizius "has completed a first-in-human study of its approach to taming the immune system’s overreaction to dialysis—with the goal of addressing the complications that can come with “angry blood.” "Invizius’ H-Guard priming solution, which is run through the machine before each procedure, coats the insides with a layer of proteins that effectively camouflage the dialysis hardware from the immune system—stealing a trick from certain bacteria that are capable of evading white blood cells, without triggering the cascading inflammatory reactions known as the complement system." Find out more about Invizius here: https://www.invizius.com/

When we built the Access EIS Fund we wanted to give our investors as much control over their portfolio as possible. How did we do it? ▪ The fund is open all year round, and each of our investors receives an individual portfolio specific to them, based on when they invest. ▪ Our investors get a personal digital dashboard, which shows them everything they need to know about their portfolio: which companies are up, which companies are down, and how far through their deployment they are. ▪ Financial advisers get a digital dashboard that allows them to set up their clients' investments into the fund, manage EIS documentation and monitor client portfolios. ▪ All of our investors can quickly and easily access and download their EIS documentation from their dashboards in order to make their tax relief claim. Start building your portfolio now with the Access EIS Fund. Our fund co-invests with proven angel investors to build large portfolios of hand-picked companies for our investors. It’s a high risk investment, and we can’t guarantee that every startup will be a unicorn, but we’re confident that our approach is the smartest on the market. Even better, we can show you the data to prove it. If you’re interested and would like to find out about the benefits of investing, book a time to speak to us directly https://lnkd.in/eq_Rc8mm Or visit us at https://lnkd.in/dUUKseZV

Congratulations to Access EIS Fund portfolio company Unibloom on its £650,000 raise! Unibloom has developed a platform that enables sustainability teams to engage operations, analyse investments, and simulate future looking projects, in real time. It brings together a highly effective combination of industry knowledge (BCorp, FMCG, sustainability leaders) and technical proficiency in complex data modelling and digitalisation. Access EIS invested in Unibloom in May 2024 Read more about the raise on Unibloom's website: https://lnkd.in/eddjPrHN

Upscore lets consumers boost their credit score to access better deals. In addition, the Finance Passport™ feature allows consumers to take their data abroad (currently Spain) and enjoy similar financial benefits. It closed its raise over £500,000 and will use the funds to expand its operations within the UK and abroad. The Access EIS Fund invested in Upscore in May 2024 Find out more about the company here: https://upscoreapp.com/

Huge congratulations to Access EIS Fund portfolio company SolasCure for their selection as a participant in Innovate UK's Global Incubator Programme! SolasCure is a pioneering biologics company committed to addressing the pressing issue of inadequate debridement, biofilm disruption, and healing solutions for chronic wounds. It's product, Aurase Wound Gel, is a hydrogel containing the proteolytic enzyme Tarumase, and aims to facilitate debridement, reduce bacterial biofilm, and promote wound bed preparation and healing, and achieve a breakthrough in wound bed preparation for patients with chronic wounds. Find out more about SolasCure: https://solascure.com/

Huge congratulations to Béa Fertility, Isabella's parents, and to Isabella: welcome! You can find out more about Béa Fertility, which produces ICI-based treatment programs to help with pregnancy, here: https://beafertility.com/

Congratulations to Access EIS Fund portfolio company MOTH Drinks - B Corp™!